Lentifactory: Horizon 2020 SME Instrument - phase I


The goal is to up-grade its scalable lentiviral bioproduction platform into GMP to provide both integrative lentiviral vectors for T-cell immunotherapies and LentiFlashTM particles for gene-editing and vaccine based therapies.

Lentifactory project: Vectalys aims to become a worldwide leader in lentiviral tools manufacturing from research to clinical reach.

Acronym: MAGIC, MAnufacturing of Gene delivery tools for Industrial and Clinical applications.

Lentifactory, a project funded from the Horizon 2020 programme, will focus on:

  • A GMP scalable manufacturing platform as a response to the lack of expert clinical manufacturing infrastructure in Europe
  • An innovative and non-integrative lentiviral particle, LentiFlash, as a response to the needs of the vaccine and gene-editing market

Fully in line with the work programme’s objectives, this project will provide a revolutionise way to  the transfection market, especially throughout Europe.

This project has received funding from the Région Occitanie and the European Union’s Horizon 2020 research and innovation programme under grant agreement No 762368.